KR102470155B1 - Oral composition for reducing body weight or body fat comprising Artemisia dracunculus and Taraxacum officinale - Google Patents

Abstract

The present invention relates to an oral composition for reducing body weight or body fat, and more particularly, contains dragon mugwort and dandelion as active ingredients to reduce body weight and body fat, as well as blood ALT, blood triglyceride and blood cholesterol. Therefore, a food composition for reducing body weight or body fat, a health functional food for reducing body weight or body fat, a composition for feed for reducing body weight or body fat, an oral pharmaceutical composition for treating or preventing obesity or metabolic lipid disease, or treating or preventing obesity or metabolic lipid disease It can be used as an oral pharmaceutical composition for animals.

Description

Oral composition for reducing body weight or body fat comprising Artemisia dracunculus and Taraxacum officinale}

The present invention relates to a composition for reducing body weight or body fat, and more particularly, to a food composition for reducing body weight or body fat comprising dragon mugwort and dandelion as active ingredients, in particular, a health functional food for reducing body weight or body fat, for reducing body weight or body fat It relates to a feed composition, an oral pharmaceutical composition for treating or preventing obesity or metabolic lipid disorders, or an oral pharmaceutical composition for animals for treating or preventing obesity or metabolic lipid disorders.

Obesity is not a disease caused by a single cause, but is caused by a combination of genetic, environmental, social, and psychological factors, so it is difficult to treat obesity with a single method. Current methods for treating obesity can be divided into lifestyle correction methods such as diet therapy, exercise therapy, and behavior therapy, drug therapy, and surgical therapy. Prior to drug or surgical treatment, active efforts to correct lifestyle should be preceded, but it is not easy to correct lifestyle, and there is a limit to the weight that can be reduced only by lifestyle correction. Therefore, in many cases, drug treatment is required along with lifestyle correction.

Although many anti-obesity drugs are being developed every year for the drug treatment of such obesity, there are not many currently available anti-obesity drugs, and most of them are limited to drugs that suppress digestion or appetite. In the case of agents that control digestion or appetite, they are classified as psychotropic drugs because of habituation, and digestive inhibitors exhibit side effects such as diarrhea and constipation. Representative obesity treatment drugs approved for long-term use by the US FDA by 2010 are norepinephrine, sibutramine (Reductil), which inhibits the reuptake of serotonin, and secreted from the pancreas and digestive system. There was orlistat (Xenical), which works by inhibiting lipase.

However, side effects such as increased blood pressure, insomnia, dry mouth, and dizziness are common, and there is a risk of cardiovascular symptoms such as myocardial infarction and stroke. In addition, side effects such as diarrhea, steatorrhea, and loss of money are common, and the use of orlistat is limited for Koreans who consume less fat than Westerners because the drug's effect is not clear.

Therefore, interest in natural materials having fewer side effects and safe anti-obesity effects on the human body is increasing.

Dragon mugwort ( Artemisia dracunculus ) is a perennial plant of the Asteraceae family, probably native to Siberia. The leaves are bright green, mildly fragrant, and taste like anise. Fresh leaves are used in salads, and vinegar brewed with fresh wormwood has a unique taste. It contains 0.3 to 1.0% of essential oil, and the main component is methyl chavicol.

Regarding Artemisia dracunculus , US Patent Publication No. 2015/0158264 discloses that yong wormwood oil can stimulate nerves when it is smelled as a fragrance or applied to the skin to exhibit a weight loss effect. It does not directly suggest the effect of reducing body weight or body fat in vivo according to the administration, and a 2018 paper by Scott Fuller et al. discloses that oral administration of yew wormwood extract increases body weight and body fat in a high-fat diet female animal model.

On the other hand, dandelion ( Taraxacum officinale ) is a perennial plant belonging to the genus Dandelion and can be found in temperate regions around the world. A naturalized plant native to Europe, it is considered a representative weed in Europe, Asia, and the Americas, but is also used for extracting medicinal ingredients or for food.

Dandelion ( Taraxacum ) Korean Patent Publication No. 2011-0114278 in relation to plants of the genus discloses an anti-obesity and antioxidant composition containing a dandelion extract, but dandelion water extract or dandelion ultrasonic water extract for 4 weeks in a high-fat diet animal model As a result of feeding the extract with the basic diet, the weight did not increase less than the control group for 4 weeks, but the weight decreased after 4 weeks compared to before the start of feeding, so the possibility of side effects due to dietary intake cannot be ruled out. , Korean Patent Publication No. 2014-0002851 discloses that dandelion ( Taraxacum platycarpum Dahlst. ) extract inhibits obesity by activating hTRPA1 (human transient receptor potential A1), but the effect of reducing body weight or body fat directly in vivo according to oral administration It is not presented, and Korean Patent Publication No. 2015-0021452 discloses that, contrary to the anti-obesity effect, dandelion alcohol extract rather suppresses the weight loss of mice caused by irradiation.

US Patent Publication No. 2015/0158264 Korean Patent Publication No. 2011-0114278 Korean Patent Publication No. 2014-0002851 Korean Patent Publication No. 2015-0021452

Fuller et al., Biology of Sex Differences 2018, 9:41 p.1-14 Yanovski SZ, Yanovski JA. N. Engl. J. Med. 2002, 346: p.591-602 Sangman Kim, Korean Journal of Obesity 1998, 7(4): p.287-92.

The problem to be solved by the present invention is to provide a food composition for reducing body weight or body fat comprising a mixture of yong mugwort extract and dandelion extract, or an extract of a mixture of yong mugwort and dandelion mixture as an active ingredient.

Another problem to be solved by the present invention is to provide a feed composition for reducing body weight or body fat comprising a mixture of yong mugwort extract and dandelion extract, or an extract of yong mugwort and dandelion mixture as an active ingredient.

Another problem to be solved by the present invention is to provide an oral pharmaceutical composition for treating or preventing obesity or metabolic lipid disease, comprising a mixture of yong mugwort extract and dandelion extract, or an extract of a mixture of yong mugwort and dandelion mixture as an active ingredient. .

Another problem to be solved by the present invention is to provide an oral pharmaceutical composition for animals for the treatment or prevention of obesity or metabolic lipid disease comprising a mixture of yong mugwort extract and dandelion extract, or an extract of a mixture of yong mugwort and dandelion mixture as an active ingredient. is to do

In order to achieve the above object, the present invention provides a food composition for weight or body fat reduction comprising a mixture of yong mugwort extract and dandelion extract, or an extract of yong mugwort and dandelion mixture as an active ingredient.

According to one embodiment of the present invention, the extract may be an extract by water, alcohol having 1 to 4 carbon atoms or a mixed solvent thereof.

According to one embodiment of the present invention, the dragon mugwort may be a stem, a leaf or an aerial part of the dragon mugwort.

According to one embodiment of the present invention, the dandelion may be a stem, leaf, aboveground outpost, root, or outpost including aboveground parts and roots of dandelion.

According to one embodiment of the present invention, the mixing ratio of the mixture of the dragon mugwort extract and the western dandelion extract or the mixing ratio of the mixture of the dragon mugwort extract and the western dandelion extract may be 1:99 to 99:1 by weight.

According to one embodiment of the present invention, the food composition may be a powder, granule, tablet, capsule, pill, extract, jelly formulation, tea bag formulation or beverage formulation.

According to one embodiment of the present invention, the food composition may be a health functional food for reducing body weight or body fat.

In addition, the present invention provides a feed composition for weight or body fat reduction comprising a mixture of dragon mugwort extract and dandelion extract, or an extract of a mixture of dragon mugwort and dandelion mixture as an active ingredient.

According to one embodiment of the present invention, the mixing ratio of the mixture of the dragon mugwort extract and the western dandelion extract or the mixing ratio of the mixture of the dragon mugwort extract and the western dandelion extract may be 1:99 to 99:1 by weight.

In addition, the present invention provides an oral pharmaceutical composition for the treatment or prevention of obesity or metabolic lipid disease comprising a mixture of dragon mugwort extract and dandelion extract, or an extract of a mixture of dragon mugwort and dandelion mixture as an active ingredient.

According to one embodiment of the present invention, the mixing ratio of the mixture of the dragon mugwort extract and the western dandelion extract or the mixing ratio of the mixture of the dragon mugwort extract and the western dandelion extract may be 1:99 to 99:1 by weight.

In addition, the present invention provides an oral pharmaceutical composition for animals for the treatment or prevention of obesity or metabolic lipid disease, comprising a mixture of dragon mugwort extract and dandelion extract, or an extract of a mixture of dragon mugwort and dandelion mixture as an active ingredient.

According to one embodiment of the present invention, the mixing ratio of the mixture of the dragon mugwort extract and the western dandelion extract or the mixing ratio of the mixture of the dragon mugwort extract and the western dandelion extract may be 1:99 to 99:1 by weight.

According to one embodiment of the present invention, the metabolic lipid disease is any one disease selected from dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, hypertension, atherosclerosis, coronary heart disease, stroke and fatty liver can be

In addition, the present invention provides a method for treating obesity or metabolic lipid disease by orally administering the composition to humans or non-human animals.

In addition, the present invention provides a new use of a mixture of dragon mugwort extract and dandelion extract or a mixture of dragon mugwort and dandelion extract for the preparation of a medicine for the treatment of obesity or metabolic lipid disease, or a medicine for animals.

The food composition for reducing body weight or body fat comprising dragon mugwort and dandelion as active ingredients of the present invention not only reduces body weight and body fat, but also reduces blood ALT, blood triglyceride and blood cholesterol, so it is a food for reducing body weight or body fat A composition, furthermore, a health functional food for reducing body weight or body fat, a feed composition for reducing body weight or body fat, an oral pharmaceutical composition for treating or preventing obesity or metabolic lipid disease, or an oral pharmaceutical composition for animals for treating or preventing obesity or metabolic lipid disease can be utilized as

Hereinafter, the present invention will be described in detail.

The inventors of the present invention evaluated body weight, body fat, blood ALT, blood triglyceride, blood cholesterol, etc. by orally administering a mixture of dragon mugwort extract and dandelion extract in a high-fat diet animal model. The effect of reducing body weight or body fat by oral administration of the mixture was confirmed.

The present invention relates to an oral composition for reducing body weight or body fat, comprising a mixture of an extract of dragon mugwort and an extract of dandelion, or an extract of a mixture of dragon mugwort and dandelion as an active ingredient.

The mixture of the dragon mugwort extract and the western dandelion extract is obtained by extracting and mixing the dragon mugwort and western dandelion separately, and may be advantageous in extraction yield and quality control compared to extracting the mixture after first mixing the dragon mugwort and western dandelion. The weight or body fat reduction effect of the mixture of dandelion extract and the extract of dragon mugwort and dandelion mixture is substantially the same.

The mixture of the dragon mugwort extract and the dandelion extract, or the extract of the mixture of the dragon mugwort and Dandelion extract is significantly superior in weight or body fat reduction efficacy compared to when the dragon mugwort extract alone or the Dandelion extract alone is orally administered.

The solid content-based mixing ratio of the mixture of the dragon mugwort extract and the dandelion extract or the mixture of the dragon mugwort and dandelion mixture based on solid content is 1: 99 to 99: 1 weight ratio, 1: 99 to 90: 10 weight ratio, 1: 99 to 80 : 20 weight ratio, 1:99 to 70:30 weight ratio, 1:99 to 60:40 weight ratio, 1:99 to 50:50 weight ratio, 1:99 to 40:60 weight ratio, 1:99 to 30:70 weight ratio, 1 : 99 to 20:80 weight ratio, 1:99 to 10:90 weight ratio, 2:98 to 50:50 weight ratio, 3:97 to 40:60 weight ratio, 4:96 to 30:70 weight ratio, 5:95 to 20: It may be 80 weight ratio, 6:94 to 10:90 weight ratio. In the case of single administration of dragon mugwort extract, there is no weight or body fat reduction effect, or even if the effect is insignificant, even if dragon mugwort extract is partially mixed with dandelion extract, the weight or body fat reduction effect is significantly increased compared to the administration of Dandelion extract alone. .

The yongsugwort extract, the dandelion extract, and the extract of the mixture of yongsugwort and dandelion may be an extract using water, alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.

The water does not need to be particularly limited if it is suitable for food production, but for example, ground water, purified water, distilled water, deionized water, etc. may be used.

The alcohol having 1 to 4 carbon atoms is not particularly limited, but for example, methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol, or normal-butanol may be used, and preferably ethanol may be used. can

The mixed solvent does not need to be particularly limited, but for example, in the case of a mixed solvent of water and ethanol, 5 to 95% by weight aqueous ethanol solution, 10 to 90% by weight aqueous ethanol solution, 20 to 80% by weight aqueous ethanol solution, 30 to 70% by weight Aqueous solutions of ethanol may be used.

The preparation of the water extract does not need to be particularly limited, but may be prepared by extracting dragon mugwort or dandelion with water at 10 to 100 ° C for 2 to 60 hours.

Preparation of the alcohol extract or the extract of the mixed solvent of water and alcohol does not need to be particularly limited, but for example, extracting dragon mugwort or dandelion with 30 to 70% by weight of ethanol aqueous solution at 20 to 60 ° C. for 2 to 48 hours can be manufactured

The extract using water, an alcohol having 1 to 4 carbon atoms or a mixed solvent thereof includes a fraction obtained by re-fractionating an extract obtained by using water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof with an organic solvent. The organic solvent may be one or more organic solvents selected from alcohol having 1 to 4 carbon atoms, hexane, acetone, ethyl acetate, chloroform and diethyl ether, and preferably hexane or ethyl acetate.

The term 'extract' used in the present invention refers to extracts obtained by extracting components included in yongsugwort, dandelion, and a mixture of yongsugwort and dandelion using the above solvent, fractions fractionated therefrom, and concentrations obtained by further concentrating these extracts or fractions. It also includes water, purified or separated purified water, and is used in the sense of including a dried product of the extract, fraction, concentrate, or purified product, or a powder obtained by pulverizing the same.

For the preparation of the purified product, a variety of additionally carried out, such as passing through an ultrafiltration membrane having a molecular weight cut-off value, or separation by various chromatography (made for separation according to size, charge, hydrophobicity or affinity). A purification method may be added.

When the dragon mugwort ( Artemisia dracunculus ) extract is mixed with a dandelion extract and administered orally as a compound, an extract such as mugwort ( Artemisia princeps Pamp.), wormwood ( Artemisia capillaris Thunb.) or wormwood ( Artemisia annua ) alone orally Compared to the case of administration, and furthermore, compared to oral administration of mugwort ( Artemisia princeps Pamp.), wormwood ( Artemisia capillaris Thunb.) or dog wormwood ( Artemisia annua ) in combination with dandelion extract, synergistic effect of weight or body fat reduction efficacy is markedly superior.

When the dandelion ( Taraxacum officinale ) extract is mixed with wormwood extract and administered orally as a compound, compared to the case of oral administration of extracts such as dandelion ( Taraxacum platycarpum ) or white dandelion ( Taraxacum coreanum ) alone, and furthermore, dandelion ( Compared to oral administration of an extract such as Taraxacum platycarpum ) or white dandelion ( Taraxacum coreanum ) in combination with a dragon mugwort extract, the synergistic effect of reducing body weight or body fat is remarkably excellent.

In addition, the dragon mugwort extract may be an extract of leaves, stems, or aerial parts of the herbaceous plant including the same, but the extract of the aerial parts of the herb is excellent in reducing body weight or body fat by oral administration.

In addition, the dandelion extract may be an extract of dandelion leaves, stems, above-ground parts containing them, roots, or whole-seed extracts including above-ground parts and roots, but the efficacy of reducing body weight or body fat by oral administration includes above-ground parts and roots The extract of the outpost to do is excellent.

The food composition of the present invention can reduce body weight or body fat, as well as blood triglyceride and blood cholesterol, by including a mixture of dragon mugwort extract and dandelion extract, or an extract of a mixture of dragon mugwort and dandelion extract as active ingredients. .

The 'food composition' is a food described in the standards and specifications of food commonly used in food manufacturing ('Food Code'), in addition to a mixture of yong mugwort extract and dandelion extract or an extract of yong mugwort and dandelion mixture as active ingredients. It may include usable food raw materials and food additives described in the Food Additive Code.

The food composition is not particularly limited, but may include, for example, carbohydrates and flavoring agents. The carbohydrates include monosaccharides such as glucose, fructose, and the like; disaccharides such as maltose, sugar, lactose and the like; oligosaccharides or polysaccharides such as dextrin, starch syrup, cyclodextrin and the like; Sugar alcohols such as xylitol, sorbitol, erythritol and the like can be used. As the flavoring agent, natural flavoring agents (thaumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) may be used.

When a food composition is prepared using the mixture of the dragon mugwort extract and the dandelion extract, or the extract of the mixture of dragon mugwort and dandelion as an active ingredient, the mixture of the dragon mugwort extract and the dandelion extract, or the extract of the mixture of dragon mugwort and dandelion can reduce body weight or body fat. It does not need to be particularly limited as long as the content exhibits efficacy, but for example, 0.1 to 99% by weight, 0.5 to 95% by weight, 1 to 90% by weight, 2 to 80% by weight, 3 to 70% by weight, 4 to 60% by weight , It may be included in 5 to 50% by weight.

In the food composition, the mixture of dragon mugwort extract and dandelion extract, or the extract of dragon mugwort extract and dandelion mixture, which are active ingredients, vary depending on the condition, weight, presence or absence of disease, and duration, but are appropriately selected by a person skilled in the art. It can be. For example, based on the daily dosage, it may be 10 to 5,000 mg, preferably 50 to 4,000 mg, more preferably 100 to 3,000 mg, and most preferably 200 to 2,000 mg per day, and the number of administrations is particularly There is no need to limit it, but a person skilled in the art can adjust it within the range of 3 times a day to 1 time a week. In the case of long-term intake for the purpose of health and hygiene or health control, it may be less than the above range.

The food composition does not need to be particularly limited, but may be, for example, a powder, granule, tablet, capsule, pill, extract, jelly formulation, tea bag formulation or beverage formulation.

In addition, in order to give weight or body fat reducing functionality to general foods, a mixture of the dragon mugwort extract and dandelion extract, or an extract of a mixture of dragon mugwort and western dandelion may be added, and foods that can be added do not need to be particularly limited, but examples For example, confectionery, bread or rice cakes, cocoa products or chocolates, meat or egg products, fish products, tofu or jelly, noodles, teas, etc. It can be added to coffee, beverages, special purpose foods, pastes, seasoning foods, dressings, kimchi, pickled fish, pickled foods, stewed foods, alcoholic beverages, raisins, and other foods. In addition, it can be added to dairy products, processed meat products, packaged meat, and egg products exemplified in the processing standards and ingredient specifications of livestock products ('Livestock Codex') according to Article 4 of the Livestock Products Sanitation Control Act.

On the other hand, the food composition containing the mixture of the dragon mugwort extract and the western dandelion extract, or the extract of the dragon mugwort and western dandelion mixture as an active ingredient is a "health functional food that helps reduce body weight or body fat", "helps improve blood neutral fat" It can be used as "health functional food" or "health functional food that helps improve blood cholesterol".

The 'health functional food' refers to food manufactured (including processing) according to legal standards using raw materials or ingredients having functional properties useful for the human body (Article 3, Subparagraph 1 of the Health Functional Food Act). The term 'health functional food' may differ in terminology or scope from country to country, but 'Dietary Supplement' in the US, 'Food Supplement' in Europe, 'Health Functional Food' or 'Health Functional Food' in Japan. It may correspond to 'Food for Special Health Use (FoSHU)' or 'Health Food' in China.

The food composition or health functional food may additionally contain food additives, and the suitability as a food additive is determined according to the standards and standards for the item in accordance with the general rules and general test methods of the 'Food Additive Code' unless otherwise specified. follow

In addition, the health functional food includes a mixture of dragon mugwort extract and dandelion extract, or a raw material notified as a 'functional raw material' used in "health functional food that helps reduce body weight or body fat" together with an extract of a mixture of dragon mugwort and dandelion mixture, or As individually recognized raw materials, Garcinia cambogia extract, conjugated linoleic acid, green tea extract, chitosan/chitooligosaccharide, complex extract such as hibiscus, green mate extract, complex such as soybean embryo extract, puer tea extract, medium-chain fatty acid-containing oil, vegetable oil diglyceride . Lactoferrin (milk refined protein), Lactobacillus gasseri BNR17, fermented vinegar pomegranate complex, wild mango seed extract, green coffee bean extract, green apple extract polyphenol (Applephenon), mate hot water extract, etc. can be used

The present invention relates to a feed composition for reducing body weight or body fat, comprising a mixture of dragon mugwort extract and dandelion extract, or an extract of a mixture of dragon mugwort and dandelion mixture as an active ingredient.

The 'feed composition' is a mixture of yong mugwort extract and dandelion extract, or a mixture of yong mugwort and dandelion mixture as active ingredients, as well as food raw materials and food additives that can be used as foods described in food standards and specifications ('Food Code') Food additives described in official regulations can be used, and even if they are not food raw materials or food additives that can be used as food, raw materials that fall under the scope of single feed in Attached Table 1 of the 'Standards and Specifications for Feed, etc.', and fall within the scope of supplementary feed under Attached Table 2 raw materials can be used.

The 'feed composition' may be an extractant in supplementary feed according to 'standards and specifications for feed, etc.', and may be a formulated feed containing the supplementary feed.

When preparing a feed composition using the mixture of the dragon mugwort extract and the dandelion extract, or the extract of the mixture of dragon mugwort and dandelion as an active ingredient, the mixture of the dragon mugwort extract and the dandelion extract, or the extract of the mixture of dragon mugwort and dandelion can reduce body weight or body fat. It does not need to be particularly limited as long as the content exhibits efficacy, but for example, 0.1 to 99% by weight, 0.5 to 95% by weight, 1 to 90% by weight, 2 to 80% by weight, 3 to 70% by weight, 4 to 60% by weight , It may be included in 5 to 50% by weight.

In the feed composition, the mixture of yong mugwort extract and dandelion extract, or the extract of yong mugwort and dandelion mixture, which are active ingredients, varies depending on the condition, weight, presence or absence of disease, and duration of the ingested animal, but is appropriately determined by a person skilled in the art. can be chosen For example, 1 to 5,000 mg, preferably 5 to 2,000 mg, more preferably 10 to 1,000 mg, even more preferably 20 to 800 mg, most preferably 50 to 500 mg, based on the daily dose The number of administrations may be adjusted within the range of three times a day to once a week by a person skilled in the art, although there is no need to specifically limit the number of administrations. In the case of long-term intake for the purpose of health and hygiene or health control, it may be less than the above range.

The present invention relates to an oral pharmaceutical composition for treating or preventing obesity or metabolic lipid disease, comprising a mixture of an extract of dragon mugwort and an extract of dandelion, or an extract of a mixture of dragon mugwort and dandelion as an active ingredient.

In addition, the present invention relates to an oral pharmaceutical composition for animals for the treatment or prevention of obesity or metabolic lipid disease, comprising a mixture of a dragon mugwort extract and a dandelion extract, or an extract of a mixture of dragon mugwort and dandelion mixture as an active ingredient.

The term 'metabolic lipid disease' as used herein may include without limitation any lipid disease induced by obesity, for example, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, hypertension, arteriosclerosis , may be any one disease selected from coronary heart disease, stroke, and fatty liver, preferably hypertriglyceridemia or hypercholesterolemia.

The 'pharmaceutical composition', 'medicine', 'veterinary pharmaceutical composition' or 'veterinary medicine' is a mixture of yong mugwort extract and dandelion extract as active ingredients, or an extract of yong wormwood and western dandelion mixture. Preparation of pharmaceutical composition, etc. It may further include suitable carriers, excipients and diluents commonly used in

The 'carrier' is a compound that facilitates the addition of the compound into cells or tissues. The 'excipient' is a compound that is added to formulate an active ingredient by giving it an appropriate form or increase the amount to make it convenient to use. The 'diluent' is a compound diluted in water that not only stabilizes the biologically active form of the subject compound, but also dissolves the compound.

The carrier, excipient, and diluent are not particularly limited, but, for example, lactose, glucose, sugar, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.

The amount of the pharmaceutical composition, drug, veterinary pharmaceutical composition, or veterinary drug used may vary depending on the age, sex, and weight of the patient or animal to be treated, and above all, the condition of the subject to be treated, a specific category of disease to be treated, or It will depend on the type, route of administration, and nature of the therapeutic used.

The pharmaceutical composition, drug, veterinary pharmaceutical composition or veterinary drug is appropriately selected according to the absorption rate of the active ingredient in the body, the rate of excretion, the age and weight, sex and condition of the patient or animal to be treated, the severity of the disease to be treated, etc. , It is generally preferred to administer 10 to 5,000 mg, preferably 50 to 4,000 mg, more preferably 100 to 3,000 mg, and most preferably 200 to 2,000 mg per day to adults. The unit dosage form formulation thus formulated can be administered several times at regular time intervals as needed.

The pharmaceutical composition, medicament, veterinary pharmaceutical composition, or veterinary medicament may be administered individually as a prophylactic or therapeutic agent, or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents.

The pharmaceutical composition may be formulated into oral preparations such as powders, granules, tablets, capsules, troches, suspensions, emulsions, syrups, aerosols and the like according to conventional methods. When formulated, it may be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.

Solid preparations for oral administration include tablets, pills, powders, granules, capsules, troches, etc., and these solid preparations contain at least one excipient such as starch, calcium carbonate, sugar or lactose, and gelatin in the compound. It can be prepared by mixing etc. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral use include suspensions, solutions for oral use, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. .

The method for treating obesity or metabolic lipid disease is to orally administer the composition to a human or non-human mammal, for example, orally administering the composition to a subject suffering from obesity or metabolic lipid disease.

There may be differences in the criteria for the above obesity depending on country, gender, or age, but based on adults, body mass index is 25 kg/m ² or more, 26 kg/m ² or more, 27 kg/m ² or more, 28 kg /m ² or more, 29 kg/m ² or more, or 30 kg/m ² or more, or if the waist circumference is 85 cm or more, 87 cm or more, 90 cm or more, or 92 cm or more in the case of a man, or If the waist circumference is 80 cm or more, 82 cm or more, 85 cm or more, or 87 cm or more, or in the case of men, the body fat percentage through bioelectrical resistance analysis is 23% or more, 25% or more, or 28% or more, For women, it could be 28% or more, 30% or more, or 33% or more.

The dosage, administration method and number of administrations for the treatment may refer to the dosage, administration method and number of administrations of the pharmaceutical composition, medicine, veterinary pharmaceutical composition or veterinary medicine.

Hereinafter, the present invention will be described in more detail with reference to preferred embodiments. However, these examples are intended to explain the present invention in more detail, and it will be apparent to those skilled in the art that the scope of the present invention is not limited thereto.

Preparation Example 1: Dragon Artemisia Water Extract (ADE) Powder

Finzelberg's "Model Number: 0 509 100MBU; Russian Tarragon powdered extract" was purchased and used as a water extract (ADE) powder of dragon mugwort. The water extract (ADE) powder of dragon mugwort was a water extract of the aerial part of dragon mugwort, and the solid content of dragon mugwort water extract was 70% by weight.

Preparation Example 2: Dandelion Ethanol Extract (TOEE) Powder

Finzelberg's "Model number: 0 195 302; Dry extract from Dandelion herb with root (65% native)" was purchased and used as dandelion ethanol extract (TOEE) powder. The dandelion ethanol extract (TOEE) powder is a 60% by weight ethanol aqueous solution extract of the whole plant including roots and aerial parts of dandelion, and the solid content of the dandelion ethanol extract was 65% by weight.

Preparation Example 3: Preparation of wormwood and dandelion extract mixture (ATEmix) powder

Dragon mugwort water extract (ADE) powder of Preparation Example 1 and Dandelion ethanol extract (TOEE) powder of Preparation Example 3 were prepared in a 9: 1 weight ratio, 7: 3 weight ratio, 5: A mixture of dragon mugwort and dandelion extract (ATEmix) powder was prepared by mixing at a weight ratio of 5, 3: 7, and 1: 9, and the mixing ratio is indicated in parentheses.

Experimental Example 1: Confirmation of changes in serological indicators

1. Preparation of experimental animals and samples

As a positive control group, 'Xenical', which is prescribed as an obesity treatment drug by inhibiting lipase secreted from the pancreas and digestive system, was purchased and used.

As experimental animals, C57BL/6J mice (6 weeks old, male) supplied by Orient Bio (Korea) were used. Sufficient supply of solid feed (no antibiotics) and water is provided until the day of the experiment, and the temperature is 21 ± 2 ℃, the relative humidity is 50 ± 15 %, and the environment is adapted for 1 week to 12 hours (light-dark cycle) before use in the experiment. did All animal testing procedures were performed in compliance with the Principles of Laboratory Animal Care of the National Institutes of Health (NIH).

A solid feed (TEKLAD CERTIFIED GLOBAL 18% PROTEIN RODENT DIET 2918 C) was provided as a general diet, and a high-fat feed (5.24 kcal/g with 60% of fat, 20% of protein and 20% of carbohydrate-derived calories) were provided. The mice were randomly assigned to a total of 6 groups, 6 mice per group, and as shown in Table 1 below, groups 1-1 of them were fed a normal diet and the rest of the groups were fed a high-fat diet for 8 weeks. Each test substance is 200 mg/kg based on the extract solid content excluding excipients in Groups 1-3 to 1-5, and 20 mg/kg based on the active ingredient of 'Xenical' in Groups 1-6. It was orally administered once a day for 8 weeks based on the amount of mL/kg administered. The normal control group and the negative control group were orally administered 10 mL/kg of physiological saline as a vehicle.

division Explanation Group 1-1 Normal control group, normal diet, physiological saline Group 1-2 Negative control group, high-fat diet, physiological saline Group 1-3 High-fat diet, Preparation Example 1, ADE 200 mg/kg Groups 1-4 High-fat diet, Preparation Example 2, TOEE 200 mg/kg Groups 1-5 High-fat diet, Preparation 3, ATEmix (5:5) 200 mg/kg Groups 1-6 Positive control group, high-fat diet, Xenical 20 mg/kg

2. Serological index analysis results

After 8 weeks of oral administration, fasting for 16 hours the next day, anesthetizes and blood is collected, and ALT (Alanine aminotransferase), triglyceride and total cholesterol contents are measured with a serum biochemistry analyzer (Accute TBA-40FR, Toshiba Medical System Co., Japan). It was measured and shown in Table 2.

division ALT(U/L) Blood triglycerides (mg/dL) blood cholesterol
(mg/dL) Group 1-1 29.3±6.0 70.7±5.2 115.5±6.1 Group 1-2 66.8±30.4 ^## 86.8±11.8 ^# 163.4±21.0 ^# Group 1-3 40.5±10.7 ^* 76.2±11.3 154.8±16.1 Groups 1-4 49.8±10.3 74.3±6.4 156.2±13.5 Groups 1-5 28.2±7.2 ^** 62.5±7.1 ^** 138.5±8.1 ^* Groups 1-6 40.7±2.7 ^* 61.5±5.0 ^** 138.2±8.6 ^*

The significant difference between the normal control group of group 1-1 and the negative control group of group 1-2 was # p<0.05, ## p<0.01; The significant difference between groups 1-2 and 1-3 to 1-6 was * p<0.05, ** p<0.01

ALT, triglyceride and total cholesterol levels were significantly increased in the negative control group of groups 1-2 fed a high-fat diet compared to the normal control group of group 1-1 fed a normal diet (p<0.01 or p<0.05).

Regarding blood ALT, ALT levels were significantly decreased in all test substance administration groups except for groups 1-4 administered with TOEE of Preparation Example 2 compared to the negative control group of groups 1-2 (p<0.05 or p<0.05). 0.01). In particular, the group administered with ATEmix (5:5) in groups 1-5 showed the lowest value at 28.2 ± 7.2 U/L.

Blood triglyceride levels were significantly decreased in groups 1-5 treated with ATEmix (5:5) and groups 1-6 treated with Xenical compared to the negative control group in groups 1-2 (p<0.05 or p<0.01 ).

Also, the blood cholesterol levels of the ATEmix (5:5)-administered group of groups 1-5 and the Xenical-administered group of groups 1-6 decreased significantly compared to the negative control group of groups 1-2 (p<0.05).

Therefore, groups 1-5 administered with ATEmix (5:5), a mixture of dragon mugwort and dandelion extract, were treated with negative control groups of groups 1-2, as well as groups administered with water extract (ADE) of dragon mugwort from groups 1-3 alone and Compared to the group administered with western dandelion ethanol extract (TOEE) alone in Groups 1-4, significant reduction effects were shown in blood ALT, triglyceride and total cholesterol, and the positive control group, Xenical-treated group in Groups 1-6 showed similar or rather superior results.

Experimental Example 2: Confirmation of weight and body fat reduction effects

1. Preparation of experimental animals and samples

Experimental animals and feed were prepared in the same manner as in Experimental Example 1. However, the test substances were prepared as shown in Table 3.

division Explanation Group 2-1 Normal control group, normal diet, physiological saline Group 2-2 Negative control group, high-fat diet, physiological saline Group 2-3 High-fat diet, Preparation 3, ATEmix (5:5) 200 mg/kg Group 2-4 Positive control group, high-fat diet, Xenical 20 mg/kg

2. Measurement results of body weight and weight loss

The body weight was measured on the test substance administration start day (before administration), and the weight was measured once a week after the start of administration, and it is shown in Table 4, and the increased weight change compared to before administration is shown in Table 5.

weight (g) Group 2-1 Group 2-2 Group 2-3 Group 2-4 0 weeks (before administration) 21.53±0.85 21.72±0.60 21.53±0.71 21.53±0.69 week 1 22.07±0.72 24.05±1.55 ^# 22.47±1.14 23.02±1.11 week 2 23.29±0.91 26.13±1.72 ^## 24.12±1.49 24.33±1.07 3rd week 23.81±0.73 28.49±2.11 ^## 25.56±1.36 ^* 26.32±1.60 4th week 25.03±1.14 32.30±2.53 ^## 27.91±1.61 ^** 29.19±1.83 5th week 25.47±1.26 36.05±3.10 ^## 29.50±2.22 ^** 31.62±1.84 ^* 6th week 26.12±1.27 39.13±3.38 ^## 31.38±2.69 ^** 33.97±1.79 ^** 7th week 26.86±1.49 41.43±3.50 ^## 33.26±2.74 ^** 35.51±2.39 ^** 8th week 26.86±1.38 43.27±3.09 ^## 33.68±2.84 ^** 36.96±2.38 ^**

The significant difference between the normal control group of Group 2-1 and the negative control group of Group 2-2 was # p<0.05, ## p<0.01; Significant difference between group 2-2 and group 2-3 and group 2-4 * p<0.05, ** p<0.01

The negative control group in group 2-2 showed a statistically significant weight gain compared to the normal diet group in group 2-1 fed a normal diet (p<0.05 or p<0.01).

The group administered with ATEmix (5:5) in Group 2-3 showed a significant weight loss compared to the negative control group in Group 2-2 from the third week of administration (p<0.05), and this phenomenon was maintained until the end of administration ( p<0.01).

The Xenical-administered group, the positive control group of Group 2-4, lost significantly compared to the negative control group of Group 2-2 from the 5th week of administration (p<0.05), and significant weight loss was observed until the end of administration ( p<0.01).

Therefore, according to the above results, it can be confirmed that the group administered with ATEmix (5:5), a mixture of dragon mugwort and western dandelion extracts in Groups 2-3, showed an immediate weight loss effect much faster than the group administered with Xenical, a positive control group in Groups 2-4. have.

Weight gain (g) Group 2-1 Group 2-2 Group 2-3 Group 2-4 0 weeks (before administration) 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 week 1 0.54±0.66 2.33±1.28 ^## 0.94±0.80 ^* 1.49±0.50 week 2 1.76±0.59 4.41±1.48 ^## 2.59±1.17 ^* 2.80±0.58 ^* 3rd week 2.29±0.47 6.77±1.92 ^## 4.03±1.32 ^** 4.79±1.09 4th week 3.50±0.63 10.59±2.37 ^## 6.38±1.59 ^** 7.66±1.30 ^* 5th week 3.94±0.78 14.33±2.99 ^## 7.97±2.17 ^** 10.09±1.42 ^** 6th week 4.59±0.75 17.41±3.19 ^## 9.84±2.56 ^** 12.44±1.42 ^** 7th week 5.33±0.87 19.71±3.30 ^## 11.73±2.64 ^** 13.98±1.98 ^** 8th week 5.34±0.79 21.55±2.87 ^## 12.15±2.83 ^** 15.43±1.90 ^**

The significant difference between the normal control group in group 2-1 and the negative control group in group 2-2 was # p<0.05, ## p<0.01; Significant differences between groups 2-2 and 2-3 and 2-4 were * p<0.05, ** p<0.01

On the other hand, when the body weight in Table 4 is converted into the amount of weight gain compared to before administration in Table 5 and compared, the ATEmix (5:5)-administered group in Group 2-3 was significantly higher than the negative control group in Group 2-2 from the first week of administration. Weight gain decreased (p<0.05), and this phenomenon was maintained until the end of administration (p<0.01).

On the other hand, the Xenical-administered group, the positive control group of Groups 2-4, showed a significant decrease in weight gain compared to the negative control group of Group 2-2 (p<0.05) at the 2nd and 4th weeks of administration (p<0.05), and it was more significant from the 5th week of administration. A decrease in body weight gain was observed (p<0.01), and the group administered with ATEmix (5:5), a mixture of dragon mugwort and dandelion extracts from groups 2-3, had a reduced weight gain compared to the group administered with Xenical, a positive control group of groups 2-4 It can be seen that the instantaneous appearance is much faster.

Experimental Example 3: Confirmation of effect according to the mixing ratio of dragon mugwort and western dandelion

1. Preparation of experimental animals and samples

As a positive control group, 'Xenical', which is prescribed as an obesity treatment drug by inhibiting lipase secreted from the pancreas and digestive system, was purchased and used.

As experimental animals, C57BL/6J mice (6 weeks old, male) supplied by Orient Bio (Korea) were used. Sufficient supply of solid feed (no antibiotics) and water is provided until the day of the experiment, and the temperature is 21 ± 2 ℃, the relative humidity is 50 ± 15 %, and the environment is adapted for 1 week to 12 hours (light-dark cycle) before use in the experiment. did All animal testing procedures were performed in compliance with the Principles of Laboratory Animal Care of the National Institutes of Health (NIH).

A solid feed (TEKLAD CERTIFIED GLOBAL 18% PROTEIN RODENT DIET 2918 C) was provided as a general diet, and a high-fat feed (5.24 kcal/g with 60% of fat, 20% of protein and 20% of carbohydrate-derived calories) were provided. Mice were randomly assigned to a total of 10 groups, with 10 mice in the normal control group and 12 mice in each group, and as shown in Table 6 below, groups 3-1 of these mice were fed a normal diet and the remaining 9 mice were fed a high-fat diet for 14 weeks. was below For each test substance, 200 mg/kg based on extract solid content excluding excipients for groups 3-3 to 3-9, and 20 mg/kg based on 'Xenical' active ingredient for groups 3-10 were 10 It was orally administered once a day for 14 weeks based on the amount of mL/kg administered. The normal control group and the negative control group were orally administered 10 mL/kg of physiological saline as a vehicle.

division Explanation Group 3-1 Normal control group, normal diet, physiological saline Group 3-2 Negative control group, high-fat diet, physiological saline Group 3-3 High-fat diet, Preparation Example 1, ADE 200 mg/kg Group 3-4 High-fat diet, Preparation Example 2, TOEE 200 mg/kg Group 3-5 High-fat diet, preparation 3, ATEmix (9:1) 200 mg/kg Group 3-6 High-fat diet, Preparation 3, ATEmix (7:3) 200 mg/kg Army 3-7 High-fat diet, preparation 3, ATEmix (5:5) 200 mg/kg Groups 3-8 High-fat diet, preparation 3, ATEmix (3:7) 200 mg/kg 3-9 groups High-fat diet, Preparation 3, ATEmix (1:9) 200 mg/kg Group 3-10 Positive control group, high-fat diet, Xenical 20 mg/kg

2. Measurement results of body weight and weight loss

The body weight was measured on the test substance administration start day (before administration), and the body weight was measured at 5 weeks, 10 weeks, and 14 weeks after the start of administration, and it is shown in Table 7, and the increased weight change compared to before administration is shown in Table 8.

weight (g) 0 weeks 5th week 10th week 14th week Group 3-1 20.61±1.26 25.27±1.08 28.95±1.52 30.59±2.11 Group 3-2 20.61±1.11 32.00±3.25 ^### 45.58±3.13 ^### 48.93±2.26 ^### Group 3-3 20.61±1.07 30.79±3.16 42.64±3.69 46.42±2.93 Group 3-4 20.61±1.00 30.06±2.45 40.13±3.05 ^** 45.09±2.87 ^* Group 3-5 20.61±0.98 30.78±2.97 41.62±3.84 ^* 45.49±3.79 Group 3-6 20.61±0.97 30.63±2.38 42.61±3.22 46.21±2.93 Army 3-7 20.61±1.00 30.48±2.44 41.14±3.22 ^* 44.61±3.83 ^* Groups 3-8 20.61±0.94 30.33±2.91 40.97±4.00 ^* 44.39±3.76 ^* 3-9 groups 20.61±0.94 29.45±2.54 39.72±4.07 ^** 42.99±5.12 ^** Group 3-10 20.61±0.99 28.56±1.18 ^* 37.33±2.45 ^** 41.36±2.43 ^**

The significant difference between the normal control group in group 3-1 and the negative control group in group 3-2 was ### p<0.001; Significant difference between group 3-2 and group 3-3 to group 3-10 * p<0.05, ** p<0.01

The negative control group of group 3-2 showed a statistically significant weight gain at 5 weeks, 10 weeks, and 14 weeks compared to the normal diet group of group 3-1 fed a normal diet (p<0.001).

The ADE-only group in Group 3-3 showed no significant weight loss at 5 weeks, 10 weeks, and 14 weeks compared to the negative control group in Group 3-2, but the TOEE-only group in Group 3-4 showed significant weight loss at 10 weeks. Significant weight loss was observed (p<0.01), and there was significant weight loss at 14 weeks, but the effect was slightly reduced compared to 10 weeks (p<0.05).

Groups 3-5 to 3-9 ATEmix-administered groups showed different patterns of weight loss according to the mixing ratio of dragon mugwort and dandelion. Groups 3-5 and 3-6, which had a relatively high mixing ratio of dragon mugwort, showed numerical weight loss compared to the negative control group of group 3-2, but only at the 10th week of group 3-5. Significant weight loss was noted. However, in groups 3-7 in which dragon mugwort and dandelion were mixed in the same weight, and in groups 3-8 and 3-9 with a relatively high mixing ratio of dandelion, both groups 3-2 were negative at 10 and 14 weeks. Significant weight loss was observed compared to the control group (p<0.05 or p<0.01).

In particular, the ATEmix (1:9)-administered group of groups 3-9, which was administered with an extract containing 90% by weight of dandelion, was significantly significant at the 10th and 14th weeks, the same as the positive control group, the Xenical-administered group of groups 3-10. significant weight loss (p<0.01).

Although there was no significant weight loss effect when yongsuk alone was administered, in groups 3-7 to 3-9 administered with an extract containing 50% by weight or more of dandelion, groups 3-4 were treated with dandelion alone. It was judged that showing a significant weight loss effect equivalent to or rather significantly exhibited a synergistic effect outside the normal expected range due to the mixture of dandelion and yongsuk.

Weight gain (g) 0 weeks 5th week 10th week 14th week Group 3-1 0.00±0.00 4.66±1.11 8.34±1.04 9.98±1.21 Group 3-2 0.00±0.00 11.39±2.64 ^### 24.98±2.56 ^### 28.32±1.99 ^### Group 3-3 0.00±0.00 10.18±3.15 22.03±3.54 25.81±2.86 Group 3-4 0.00±0.00 9.45±2.64 19.52±3.05 ^** 24.48±2.78 ^* Group 3-5 0.00±0.00 10.18±2.58 21.01±3.50 ^* 24.88±3.55 Group 3-6 0.00±0.00 10.03±1.92 22.00±3.03 25.60±2.79 Army 3-7 0.00±0.00 9.88±2.49 20.53±3.44 ^** 24.00±4.25 ^* Groups 3-8 0.00±0.00 9.72±2.27 20.36±3.28 ^** 23.78 ± 3.19 ^** 3-9 groups 0.00±0.00 8.84±2.72 19.11±4.17 ^** 22.38±5.27 ^** Group 3-10 0.00±0.00 7.95 ± 0.95 ^** 16.73±1.63 ^** 20.75±1.69 ^**

The significant difference between the normal control group in group 3-1 and the negative control group in group 3-2 was ### p<0.001; Significant difference between group 3-2 and group 3-3 to group 3-10 * p<0.05, ** p<0.01

When the body weight in Table 7 is converted into weight gain compared to before administration as shown in Table 8 and compared, the ATEmix (5:5) administration group in Groups 3-7 and the TOEE alone administration group in Groups 3-4 showed significantly significant results at 10 weeks. Weight loss was observed (p<0.01), and there was significant weight loss at 14 weeks, but the effect was slightly reduced compared to 10 weeks (p<0.05).

On the other hand, the ATEmix (3:7)-administered group of groups 3-8 and the ATEmix (1:9)-administered group of groups 3-9, which were administered with an extract containing 70% by weight or more of dandelion, were the positive control groups of groups 3-10, Xenical In the same way as in the administration group, both the 10th and 14th weeks of administration showed a significant decrease in body weight gain compared to the negative control group of group 3-2 (p<0.01).

3. Body fat mass, epididymal fat and liver tissue weight measurement results

After the animals were anesthetized on the last day of administration, the fat mass and lean mass were measured using dual energy X-ray absorptiometry (InAlyzer, Medikors), and the animals were fasted for 16 hours. After anesthesia and autopsy, visual inspection of the animal's abdominal organs was performed to confirm the presence or absence of abnormalities in the internal organs, and epididymal fat tissue and liver were removed and weighed, and are shown in Table 9.

division body fat (g) muscle mass (g) Epididymal fat (g) Liver (g) Group 3-1 8.837±2.003 21.250±1.223 0.688±0.275 1.065±0.064 Group 3-2 22.357±1.117 ^### 26.384±1.654 ^### 2.183±0.350 ^### 1.670±0.368 ^### Group 3-3 21.230±1.849 25.081±2.153 2.042±0.559 1.444±0.321 Group 3-4 20.139±1.917 24.761±1.593 1.815±0.450 1.241±0.274 ^** Group 3-5 20.760±2.369 24.745±1.960 1.856±0.535 1.298±0.391 ^* Group 3-6 20.844±2.091 25.074±1.987 2.018±0.512 1.366±0.314 Army 3-7 20.258±2.437 24.476±2.279 1.876±0.212 1.231±0.180 ^** Groups 3-8 20.563±1.720 23.617 ± 2.447 ^** 1.672±0.370 ^* 1.243±0.348 ^** 3-9 groups 19.555 ± 3.462 ^* 23.164 ± 2.454 ^** 1.618±0.394 ^** 1.108±0.250 ^** Group 3-10 17.812 ± 1.560 ^** 23.203 ± 1.725 ^** 1.458±0.294 ^** 0.983±0.084 ^**

The significant difference between the normal control group in group 3-1 and the negative control group in group 3-2 was ### p<0.001; Significant difference between group 3-2 and group 3-3 to group 3-10 * p<0.05, ** p<0.01

The negative control group of group 3-2 showed a statistically significant increase in body fat, muscle mass, epididymal fat weight and liver tissue weight increase compared to the normal diet group 3-1 group fed a normal diet (p<0.001 ).

The group administered with ADE alone in Groups 3-3 showed no significant difference in body fat, muscle mass, weight of epididymal fat and weight of liver tissue compared to the negative control group in Group 3-2. There was no significant difference in body fat, muscle mass, and epididymal fat weight of group 3-2 compared to the negative control group, and a significant decrease was shown only in liver tissue weight compared to the negative control group of group 3-2 (* p<0.05).

Groups 3-5 to 3-9, which were administered with ATEmix, showed different patterns in body fat, muscle mass, epididymal fat weight, and liver tissue weight according to the mixing ratio of dragon mugwort and dandelion.

The ATEmix (9:1) administered group in Group 3-5 did not show significant differences in body fat, muscle mass, and epididymal fat weight with the negative control group in Group 3-2, and the liver tissue was significantly lower than that of the negative control group in Group 3-2. A significant decrease was shown only in weight (* p<0.05). The ATEmix (7:3) administration group of group 3-6 showed no significant difference from the negative control group of group 3-2 in body fat, muscle mass, epididymal fat weight and liver tissue weight.

Groups 3-7, 3-8, and 3-9 administered with an extract containing 50% by weight or more of dandelion significantly reduced liver tissue weight compared to the negative control group in group 3-2. (** p<0.01), and group 3-8 and group 3-9, which were administered with an extract containing 70% by weight or more of dandelion, had higher muscle mass and epididymal fat weight than the negative control group in group 3-2. significantly decreased (* p<0.05 or ** p<0.01), and the body fat mass of groups 3-9 administered with the extract containing 90% by weight of dandelion was also significantly higher than that of the negative control group of group 3-2. decreased significantly (p<0.05).

4. Histological examination of liver tissue

After oral administration for 14 weeks was completed, the next day after fasting for 16 hours, anesthesia was performed, autopsy was performed, and livers were removed and fixed in 10% neutral buffered formalin solution. The fixed liver tissue went through general tissue processing procedures such as trimming, dehydration, and paraffin embedding to prepare a paraffin block, cut to 4 μm, and then stain with Hematoxylin & Eosin (H&E).

In order to analyze the degree of fatty inflammation in liver tissue, the inflammation score was evaluated through the evaluation method used in the non-alcoholic fatty liver model. Inflammation scores in the liver tissue were given as 0 points for no inflammatory lesions, 1 point for less than 2 sites magnified 200 times, 2 points for 2-4 sites, and 3 points for more than 4 sites, and are shown in Table 10 [ Hepatology. 2005 Jun; 41(6):1313-21].

division Inflammation score in liver tissue Group 3-1 0.00±0.00 Group 3-2 1.00±0.00 ^### Group 3-3 0.92±0.29 Group 3-4 0.50±0.52 ^* Group 3-5 0.42±0.51 ^* Group 3-6 0.75±0.45 Army 3-7 0.42±0.51 ^* Groups 3-8 0.33±0.49 ^** 3-9 groups 0.33±0.49 ^** Group 3-10 0.17±0.39 ^**

The significant difference between the normal control group in group 3-1 and the negative control group in group 3-2 was ### p<0.001; Significant difference between group 3-2 and group 3-3 to group 3-10 * p<0.05, ** p<0.01

Compared to the normal control group of group 3-1 fed a normal diet, the inflammation score in the liver tissue was significantly increased in the negative control group of group 3-2 fed a high-fat diet (p<0.001).

Groups 3-3 ADE alone did not show a significant difference from the negative control group in Group 3-2 in the inflammation score in liver tissue, and the TOEE-only group in Groups 3-4 was the negative control group in Group 3-2. and showed a significant difference (* p<0.05).

Groups 3-5 to 3-9 treated with ATEmix showed different patterns in body fat, muscle mass, epididymal fat weight and liver tissue weight according to the mixing ratio of dragon mugwort and dandelion. Only the ATEmix (7:3)-administered group in Groups 3-6 showed no significant difference from the negative control group in Groups 3-2 in the inflammation score in the liver tissue. In both groups 3-8 and 3-9, compared to the negative control group in group 3-2, the inflammation score in the liver tissue showed a significant decrease (* p<0.05 or **p<0.01), and dragon mugwort and Western In the mixing ratio of dandelion, as the mixing ratio of Western dandelion increased, the inflammation score in liver tissue showed a tendency to decrease. In particular, in the case of groups 3-7, 3-8, and 3-9, in which the mixing ratio of dandelion was 50% or more, the inflammation score in the liver tissue was higher than that of groups 3-4, which were treated with dandelion (TOEE) alone. It was judged to show a synergistic effect outside the normal expected range due to the mixture of dragon mugwort and western dandelion.

statistical analysis

The experimental results of Experimental Examples 1 to 3 are expressed as mean ± standard deviation, Levene's test was performed to compare the homogeneity of variance for all data, and a significant difference with the control group was performed by one-way analysis of variance (ANOVA). Dunnett's test was performed to find out the test group with A P value of less than 0.05 was considered statistically significant.

Examples of formulations of compositions containing the extract of the present invention are described below, but the present invention is not intended to limit them, but is intended to be specifically described.

Formulation Example 1: Preparation of powder

Dragon mugwort and dandelion extract mixture powder of Preparation Example 3 20 mg

lactose 100 mg

Talc 10 mg

A powder is prepared by mixing the above ingredients and filling them in an airtight bag.

Formulation Example 2: Preparation of tablets

Dragon mugwort and dandelion extract mixture powder of Preparation Example 3 10 mg

Corn Starch 100 mg

Lactose 100 mg

Magnesium stearate 2 mg

After mixing the above ingredients, tablets are prepared by tableting according to a conventional tablet manufacturing method.

Formulation Example 3: Preparation of capsule formulation

Dragon mugwort and dandelion extract mixture powder of Preparation Example 3 10 mg

3 mg of crystalline cellulose

Lactose 14.8 mg

Magnesium stearate 0.2 mg

Capsules are prepared by mixing the above ingredients and filling them into gelatin capsules according to a conventional capsule preparation method.

Formulation Example 4: Preparation of granules

Dragon mugwort and dandelion extract mixture powder of Preparation Example 3 1,000 mg

Appropriate amount of vitamin mixture

Vitamin A Acetate 70 μg

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

Vitamin B2 0.15 mg

Vitamin B6 0.5 mg

Vitamin B12 0.2 μg

Vitamin C 10 mg

10 μg of biotin

Nicotinamide 1.7 mg

Folic acid 50 μg

Calcium Pantothenate 0.5 mg

Appropriate amount of mineral mixture

Ferrous sulfate 1.75 mg

Zinc Oxide 0.82 mg

Magnesium Carbonate 25.3 mg

Potassium Phosphate Monobasic 15 mg

Dibasic Calcium Phosphate 55 mg

Potassium citrate 90 mg

Calcium Carbonate 100 mg

Magnesium Chloride 24.8 mg

The composition ratio of the above vitamin and mineral mixture is a mixture of ingredients suitable for health functional food in a preferred embodiment, but the mixing ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health functional food manufacturing method. Next, granules can be prepared and used in the preparation of health functional food compositions according to conventional methods.

Formulation Example 5: Preparation of beverage formulation

Dragon mugwort and dandelion extract mixture powder of Preparation Example 3 1,000 mg

Citric Acid 1,000 mg

100 g of oligosaccharides

2 g plum concentrate

1 g of taurine

Add purified water to total 900 mL

After mixing the above ingredients according to the usual beverage manufacturing method, stirring and heating at 85 ° C. for about 1 hour, the resulting solution is filtered and collected in a sterilized 2 L container, sealed and sterilized, and then refrigerated according to the present invention. It is used for the preparation of functional beverage compositions.

Formulation Example 6: Preparation of feed composition

Dragon mugwort and dandelion extract mixture (ATEmix) powder of Preparation Example 3 0.1 kg, corn 25.5 kg, wheat 15.04 kg, wheat flour 8.15 kg, rice bran 7.4 kg, soybean meal 18 kg, jade gluten 1 kg, chicken by-products 14 kg, animal fat 9 kg, processing salt 0.3 kg, tricalcium phosphate 0.3 kg, limestone 1 kg, choline chloride 0.01 kg, vitamins 0.05 kg, minerals 0.05 kg, and digestive enzymes 0.1 kg were mixed to prepare an animal (dog, pet dog) feed composition.

Claims (15)

In the food composition for weight and body fat reduction comprising a mixture of dragon mugwort extract and dandelion extract as an active ingredient,
The dragon mugwort extract is a water extract of dragon mugwort,
The composition lowers body weight and body fat and at the same time lowers blood triglycerides, blood cholesterol and fatty inflammation in liver tissue,
A food composition for reducing body weight and body fat, characterized in that the mixing ratio of the mixture of the dragon mugwort extract and the western dandelion extract is 10:90 to 50:50 in weight ratio. The food composition for reducing weight and body fat according to claim 1, wherein the dandelion extract is an extract obtained by water, alcohol having 1 to 4 carbon atoms or a mixed solvent thereof. The food composition for reducing body weight and body fat according to claim 1, wherein the yongsuk is a stem, leaf or aerial part of the yongsugwort. The food composition for reducing body weight and body fat according to claim 1, wherein the dandelion is a stem, leaf, aboveground outpost, root, or an outpost comprising aboveground parts and roots of dandelion. delete According to claim 1, wherein the food composition is powder, granules, tablets, capsules, pills, extracts, jelly formulations, tea bag formulations or food composition for reducing body fat, characterized in that the beverage formulation. The food composition for reducing body weight and body fat according to claim 1, wherein the food composition is a health functional food for reducing body weight and body fat. In the feed composition for reducing body weight and body fat comprising a mixture of dragon mugwort extract and dandelion extract as an active ingredient,
The dragon mugwort extract is a water extract of dragon mugwort,
The composition lowers body weight and body fat and at the same time lowers blood triglycerides, blood cholesterol and fatty inflammation in liver tissue,
The mixing ratio of the mixture of the dragon mugwort extract and the western dandelion extract is 10: 90 to 50: 50 weight ratio, characterized in that the weight and body fat reduction feed composition. delete In the oral pharmaceutical composition for the treatment or prevention of obesity and metabolic lipid disorders comprising a mixture of dragon mugwort extract and dandelion extract as an active ingredient,
The dragon mugwort extract is a water extract of dragon mugwort,
The composition lowers body weight and body fat and at the same time lowers blood triglycerides, blood cholesterol and fatty inflammation in liver tissue,
The mixing ratio of the mixture of the dragon mugwort extract and the western dandelion extract is 10: 90 to 50: 50 in weight ratio,
Obesity and metabolic lipids, characterized in that the metabolic lipid disease is any one disease selected from dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, hypertension, arteriosclerosis, coronary heart disease, stroke and fatty liver An oral pharmaceutical composition for treating or preventing a disease. delete delete In the oral pharmaceutical composition for animals for the treatment or prevention of obesity and metabolic lipid disorders comprising a mixture of dragon mugwort extract and dandelion extract as an active ingredient,
The dragon mugwort extract is a water extract of dragon mugwort,
The composition lowers body weight and body fat and at the same time lowers blood triglycerides, blood cholesterol and fatty inflammation in liver tissue,
The mixing ratio of the mixture of the dragon mugwort extract and the western dandelion extract is 10: 90 to 50: 50 in weight ratio,
Obesity and metabolic lipids, characterized in that the metabolic lipid disease is any one disease selected from dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, hypertension, arteriosclerosis, coronary heart disease, stroke and fatty liver Oral animal pharmaceutical composition for treating or preventing disease. delete delete